News & Publications

Read about the latest company news, thought leadership, publications and events


14 December 2021Cerecin Announces Appointment of Milan Vinnola as General Counsel

09 November 2021Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin in the Treatment of Infantile Spasms

19 October 2021Cerecin raises $40 Million Series II and IIA financing to support its programs in neurological disorders

04 February 2021Julie Liu Joins Cerecin From Pfizer as New Vice President of R&D and Chemicals, Manufacturing and Controls

17 December 2020Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)

04 November 2020Cerecin Announces Presentations of Tricaprilin Data at CTAD 2020

29 October 2020Cerecin Announces Orphan Drug Designation from U.S. FDA for Tricaprilin in the Treatment of Infantile Spasms

08 October 2020U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin’s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms

30 July 2020Cerecin Presents New Data on Tricaprilin at Alzheimer's Association International Conference 2020

29 July 2020Cerecin Sponsors Alzheimer’s Disease Association (ADA) Walk2Remember 2020

December 20, 2019Cerecin appoints biotech veteran Joseph S. Zakrzewski as its new Chairman

November 4, 2019Bruce Morimoto joins Cerecin as Vice President of Drug Development

October 7, 2019Lilian Chow joins Cerecin as Vice President of Clinical Operations and Regulatory Affairs

January 7, 2019Cerecin appoints Dr. Xiaoping Cao as Head of CMC

December 11, 2018Cerecin Sponsors and Presents at Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium

October 24, 2018Cerecin appoints veteran Singaporean Pharmaceutical Executive, Cheryl Tan, as Head of Commercial Strategy

October 16, 2018Cerecin appoints two new members to its Scientific Advisory Board following announcement of new Singapore headquarters

October 4, 2018Accera closes new investment led by Asia's leading agribusiness group, Wilmar, and rebrands as Cerecin

September 12, 2018Dr. Charles Stacey, Cerecin's President and CEO is appointed to the Board of Governors of the Accreditation Council for Medical Affairs (ACMA)

July 12, 2017Cerecin Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio for Cerecin's Technology in Korea

May 4, 2017Cerecin appoints Dr. Judy Walker as Chief Medical Officer

February 28, 2017Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's Disease

November 30, 2016Beyond the Failed Beta Amyloid Hypothesis

September 26, 2016Accera to Present at Upcoming Healthcare and Investor Conferences

September 8, 2016Accera Appoints Jeffrey Cummings and Bruno Vellas to Scientific Advisory Board

August 2, 2016Accera Appoints C. Evan Ballantyne as Chief Financial Officer

May 12, 2016Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for Alzheimer's Disease Treatment

April 27, 2016Broomfield Biotech Firm Accera Moves to Boulder

April 20, 2016Bioscience roundtable: Attracting development capital, talent top of mind in Colorado

March 10, 2016Accera to Present at BIO Asia International Conference

March 8, 2016Accera Appoints Ernest Wong, Ph.D., as Head of Corporate Development

September 17, 2015Accera Supports World Alzheimer's Day

July 14, 2015Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease

June 10, 2015Accera Appoints Dr. Charles Stacey, M.D., as President and CEO

February 20, 2015Dr. Samuel Henderson, Accera's V.P. of Research and Development, to Present at the 249th American Chemical Society National Meeting

January 14, 2014Accera statement on FDA warning letter

November 12, 2013Accera, Inc. to Moderate Symposium on Metabolic Dysregulation in Alzheimer's Disease During the 6th Annual Clinical Trials Conference on Alzheimer's Disease (CTAD)

October 28, 2013Accera, Inc. Announces Publication of Results in the Journal Neuropsychiatric Disease and Treatment of a Retrospective Cohort Study Examining the Effects of Axona® in Patients With Mild-to-Moderate Alzheimer's Disease

April 9, 2013Accera and the University of Miami Miller School of Medicine Announce Collaboration to Study Axona® for Cognitive Impairment in Patients with Multiple Sclerosis

March 1, 2013Accera, Inc. Introduces Axona® Patient Starter Kits for Alzheimer's Disease Patients Beginning Therapy

October 5, 2010Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimer's Disease

March 9, 2010New Evidence Further Validates Ketone Body Therapy as an Effective Approach in Managing Alzheimer's Disease

February 1, 2010Accera, Inc. to Present at the 3rd Annual European Life Science CEO Forum for Partnering & Investing

November 23, 2009Tips for Caregivers and a New Therapy Offers Hope in the Fight Against Alzheimer's

November 17, 2009Accera, Inc. Announces Culmination of Lost & Found Campaign: Company Donates '$'25,000 to the Alzheimer's Foundation of America for National Memory Screening Day

November 11, 2009Accera, Inc. Awarded "Company of the Year" by the Colorado BioScience Association

November 11, 2009Accera, Inc. to Present at Lazard Capital Markets 6th Annual Healthcare Conference

September 18, 2009Accera Inc. to Present at UBS Global Life Sciences Conference

August 12, 2009Accera Announces Peer-Reviewed Publication of the Results of its 90-day Clinical Study of AC-1202 (Axona™) in Mild to Moderate Alzheimer's Disease

August 11, 2009Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day through On-line Awareness Effort

July 27, 2009Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of Directors

July 14, 2009Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease

April 15, 2009Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

March 25, 2009Accera, Inc. to Present at Upcoming Investor Conferences

March 24, 2009Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors

March 2, 2009Accera Launches Axona™, First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

February 19, 2009Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference


Application of FibroScan for hepatic safety monitoring in early clinical studies
Sabina Paglialunga, PhD, Terry O’Reilly, MD CPI, Samuel Henderson, PhD, Bruce H Morimoto, PhD, Lilian Chow, MRDM, Nor Rahimah binte Ramli, Lars Nelleman, MD, Judith Walker, MD
2021 ACCP Virtual Annual Meeting

Administering tricaprilin after a meal optimises bioavailability and minimises adverse events
Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Bruce Morimoto, PhD
Clinical Trials on Alzheimer’s Disease 2020

Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese
Bruce H. Morimoto, PhD; Lilian Chow, MRDM; Lars Nelleman,MD; Judith Anne Walker, MD
Clinical Trials on Alzheimer’s Disease 2020

An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD
Judith Anne Walker, MD; Lars Nelleman,MD; Bruce H Morimoto, PhD; Lilian Chow, MRDM
Clinical Trials on Alzheimer’s Disease 2020

Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses up to 30g BID
Lilian Chow, MRDM; Lars Nelleman, MD; Bruce H. Morimoto, PhD; Judith Anne Walker, MD
Clinical Trials on Alzheimer’s Disease 2020

Development of tricaprilin, a ketogenic drug for Alzheimer's disease
Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Samuel T Henderson, PhD
Alzheimer's Association International Conference 2020

The rat as a model for CER-0001 formulation development
Samuel T Henderson, PhD, Ameet Ambarkhane PhD, Bruce Morimoto, PhD, and Judith Walker, MD
Alzheimer's Association International Conference 2020

A Review of Ketogenic Therapies for Alzheimer’s Disease
S. Henderson
Metabolic Health Summit 2019


9–12 November, 2021Clinical Trials on Alzheimer's Disease conference (CTAD)

19–23 October, 20217th Global Symposium on medical ketogenic dietary therapies

September 8 – 12, 2021IHC 2021 – International Headache Congress – IHS and EHF joint congress 2021

25–27 August, 2021ISPE Singapore Conference & Exhibition 2021

25–26 August, 2021Annual Biomarkers for Alzheimer’s Disease Summit

26-30 July, 2021Alzheimer's Association International Conference (AAIC)

13-15 July, 2021Healthy Ageing APAC Summit

7–8 July, 2021DIA-CoRE Singapore Annual Meeting 2021

27 June–1 July, 2021DIA 2021 Global Annual Meeting

10-13 June 202113th Asian and Oceanian Epilepsy Congress (AOEC)

28-30 April, 20214th Annual Neuroscience Innovation Forum

25-28 April, 2021The World Orphan Drug Congress USA 2021

17–21 April, 2021American Academy of Neurology Annual Meeting (AAN Annual Meeting)

17–25 March, 2021Online Migraine World Summit 2021

8-10 October, 2020International Congress of the Asian Society against Dementia, ASAD 2020 Virtual Meeting

13-14 October, 2020Precision in Clinical Trials Virtual Summit

15 October, 2020Solebury Trout Virtual Private Company Showcase

11-13 November, 2020TIDES Europe: Oligonucleotide & Peptide Therapeutics

8-10 December, 2020Phar-East 2020